• Injection Sites: Target areas include the lip body, vermillion border, and philtrum columns, utilizing the precision delivery of the syringe system.
• Pain Management: Features co-formulated 0.3% lidocaine to minimize patient discomfort, though additional topical anesthesia remains optional at the practitioner’s discretion.
• Safety & Technique: Strict aseptic technique is mandatory. Use extreme caution to prevent intravascular injection within the highly vascular perioral region.
• Post-Treatment Care: Instruct patients to avoid sun exposure, UV light, and extreme temperatures until any initial redness and swelling have fully resolved.
• Adverse Risks: Key warnings and potential complications include transient bruising, swelling, vascular occlusion, skin necrosis, and visual disturbance.

• Indicated for lip augmentation, including precise volume enhancement, lip border definition, and correction of volume loss.
• Indicated for the perioral treatment area, including vermillion border definition, philtrum columns, and perioral lines.
• Designed for precision shaping and multi-layer lip protocols alongside higher-volume fillers.
• Prescribed for use by licensed aesthetic medicine professionals only; not for self-administration.

Product Specifications

• Active ingredient: Cross-linked hyaluronic acid 18.5 mg/g; 0.3% lidocaine; contains mannitol.
• Format: Injectable gel supplied in 1 × 1 mL prefilled syringe (BI-FLEX® syringe system) with 2 × 30G ½ needles.
• Manufacturer: Laboratoires VIVACY, France.
• Drug class: Injectable cross-linked hyaluronic acid filler for lip augmentation; BI-FLEX® syringe system; with lidocaine.
• Packaging: Magenta/purple and white box (updated visual identity under the BI-FLEX® rebrand).
• Regulatory status: CE-marked for EU use; US FDA status should be verified by jurisdiction before procurement.

Contraindications

• Known hypersensitivity to hyaluronic acid.
• Known hypersensitivity to lidocaine or other amide-type local anesthetics.
• Active infection, inflammation, or dermatological condition in the treatment area.
• Active herpes labialis affecting the perioral region.
• Pregnancy and breastfeeding, as a precautionary measure.
• Any condition listed in the current Instructions for Use (IFU).

• Inject into lip tissue only; the BI-FLEX® syringe supports precise delivery in the delicate lip treatment area.
• Topical anesthesia is optional, as lidocaine is co-formulated at 0.3%.
• Allow the syringe to reach room temperature before administration.
• The product is intended for single use only; discard any unused gel, syringe, and needle after the procedure.
• Screen for hypersensitivity to hyaluronic acid and amide-type anesthetics before treatment and refer to the full IFU.

STYLAGE® SPECIAL LIPS BI-FLEX® with Lidocaine is a CE-marked medical device manufactured by Laboratoires VIVACY (France). Its regulatory status in other jurisdictions, including the United States, should be verified before procurement. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact the Med Supply Solutions support team for sourcing information and documentation support.

1. Steenen SA, Bauland CG, van der Lei B, et al. Head-to-head comparison of 4 hyaluronic acid dermal fillers for lip augmentation: A multicenter randomized, quadruple-blind, controlled clinical trial. J Am Acad Dermatol. 2023;88(4):932-935. doi:10.1016/j.jaad.2022.11.012
2. Ramos-E-Silva M, Fonteles LA, Lagalhard CS, Fucci-da-Costa AP. STYLAGE®: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature. Clin Cosmet Investig Dermatol. 2013;6:257-261. Published 2013 Oct 23. doi:10.2147/CCID.S35251

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.